Acute and Sub-acute Hypoglycaemic Evaluation of Cassia nodosa Leaves in Normal and Streptozotocin Induced Diabetic Rats | Chapter 7 | Pharmaceutical Research - Recent Advances and Trends Vol. 4

 

In the present work, one novel ornamental plant Cassia nodosa Buch.-Ham. ex Roxb. has been investigated for antidiabetic potential. It aimed to check the hypoglycaemic effect of C. nodosa leaves on normal and streptozotocin-induced diabetic rats by acute and sub-acute studies. The qualitative and quantitative phytochemistry of the leaf drug was carried out by standard procedures. In preliminary phytochemistry antidiabetic compounds such as alkaloids, glycosides, steroids, flavonoids and saponins were detected. Quantitative phytochemistry revealed the presence of significant amounts of saponins (9.52%) and alkaloids (4.08%). Prior to the hypoglycaemic study, acute oral toxicity testing of the drug was performed. Later the effects of single and multiple doses of test drug were studied using various parameters. Dried powdered leaf material was used as an oral drug. Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin. Single and multiple doses of test drug (0.5 g/kg body weight/day) were given to normal and diabetic rats. The parameters studied were blood glucose, serum cholesterol, serum triglycerides and serum proteins. The results of the test drug were compared with standard hypoglycaemic drug-glibenclamide (0.01 g/kg/day). It was done by the ‘Student’s ‘t’ test’ and the one-way ANOVA test. Unlike acute, sub-acute treatment of test drug showed a highly significant reduction (40.29%) in blood glucose levels of diabetic rats in 10 days. This effect was considerably good in comparison with standard drug (63.51%). The test drug and standard drug exhibited an insignificant change in the abnormal levels of serum metabolites of diabetic rats. Preclinically C. nodosa was proved to be an effective hypoglycaemic agent. Further studies are necessary to elucidate details of active phytochemicals and their mechanism of hypoglycaemic action.

 

Author(s) Details

Urmila C. Kumavat
Research Laboratory, Department of Botany, VPM’s B.N. Bandodkar College of Science (Autonomous), Thane (W) 400601, Affiliated to University of Mumbai, Maharashtra, India.

 

Please see the book here:- https://doi.org/10.9734/bpi/prrat/v4/1397

Ameliorative Impact of Tecoma stans on Streptozotocin-Induced Diabetic Cardiomyopathy in Wistar Rats | Chapter 2 | Advanced Concepts in Pharmaceutical Research Vol. 1

 The objective concerning this study was to visualize how an ethanolic extract of Tecoma stans overwhelmed diabetic cardiomyopathy in wistar rats after streptozotocin-inferred diabetes.  The pathogenesis of diabetic cardiomyopathy (DCM) is complex, and the therapeutic alternatives available to treat DCM are restricted. A single intravenous portion of drug or other consumable of (Streptozotocin 45 mg/kg) produced diabetes in male wistar rats. Blood pressure, antitoxin lactate dehydrogenase (LDH), hydrogen apolipoprotein B, and lipids were measured, in addition to heart pressure, caspase-3, sodium potassium adenosine triphosphatase (Na + -K + ATPase), and DNA laddering.  The obtained result granted that the administration of ethanolic extract of Tecoma stans (120 mg/kg/p.o.) considerably (P < 0.01) reduced myocyte deficit by suppressing the levels of cardiac caspase-3, DNA laddering; mean unmodified blood pressure and heart rate in addition to serum LDH, organic compound composed of carbon, apolipoprotein B and lipids levels. Further, it augmented the soul weight and cardiac Na+ K + ATPase activity in diabetic rats. Finally, an flammable liquid extract of Tecoma stans was found to have important anti-apoptotic potential in Streptozotocin-inferred diabetic cardiomyopathy.

Author(s) Details:

S. Kameshwaran,
Department of Pharmacology, SSM College of Pharmacy, Bhavani (Tk), Erode (Dt), Tamilnadu - 638 312, India.

M. Ravisankar,
Department of Pharmacy, Vinayaka Mission’s College of Pharmacy, Vinayaka Mission’s Research Foundation (Deemed to be a University), Salem, Tamilnadu - 636 308, India.

P. Srinivasan,
Department of Pharmacology, Vivekanandha Pharmacy College for Women, Sankari West, Salem -637303, India.

V. Suresh,
Department of Pharmacology, Arunai College of Pharmacy, Tiruvannamalai 606 603, India.

Please see the link here: https://stm.bookpi.org/ACPR-V1/article/view/12073

Study on Anti-Diabetic effects of [10]-Gingerol in Streptozotocin and High-Fat Diet-Induced Diabetic Rats | Chapter 5 | Technological Innovation in Pharmaceutical Research Vol. 10

 Experiments have shown that its active ingredients [10] -gingerol has anti-diabetic properties in diabetic rats produced by streptozotocin (STZ) and a high-fat diet (HFD). Type 2 diabetes mellitus is quickly spreading among the world's population. With 62.4 million people living with type 2 diabetes, India is known as the "diabetes capital of the world." Insulin and oral hypoglycemic medicines such as sulfonylurea derivatives, thiazolidinediones, biguanides, and -glucosidase inhibitors are currently used to treat type 2 diabetes, but these medications have the majority of the negative effects. Wistar rats (150–200 g) were housed in groups of six (n=6) under a 12-hour light/dark cycle with controlled temperature and humidity (252°C, 55–65 percent relative humidity). In the pancreas of vehicle-treated animals, histological analysis revealed normal acini and cellular population in the islets of Langerhans. Our findings revealed that [10]-gingerol exerted anti-diabetic action in a dose-dependent manner. This research could help us better understand the role of [10]-gingerol in diabetic mellitus treatment.

Author (S) Details

Ashutosh Kumar Yadav
Department of Pharmacology, K.R. Mangalam University, Sohna Road, Gurgaon, India.

Reetu
Department of Pharmaceutics, K.R. Mangalam University, Sohna road, Gurgaon, India.

Arun Garg
Department of Pharmacology, K.R. Mangalam University, Sohna Road, Gurgaon, India.

View Book :- https://stm.bookpi.org/TIPR-V10/article/view/2842